Wall Street brokerages predict that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will announce ($0.21) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Pieris Pharmaceuticals’ earnings, with estimates ranging from ($0.21) to ($0.20). Pieris Pharmaceuticals reported earnings of ($0.14) per share in the same quarter last year, which indicates a negative year over year growth rate of 50%. The company is scheduled to report its next quarterly earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full year earnings of ($0.83) per share for the current year, with EPS estimates ranging from ($0.84) to ($0.82). For the next year, analysts expect that the company will report earnings of ($0.85) per share, with EPS estimates ranging from ($0.86) to ($0.83). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Pieris Pharmaceuticals.

A number of brokerages recently issued reports on PIRS. HC Wainwright set a $9.00 target price on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 11th. BidaskClub cut shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 26th. Finally, TheStreet cut shares of Pieris Pharmaceuticals from a “c-” rating to a “d-” rating in a research report on Monday, June 12th. Four equities research analysts have rated the stock with a buy rating, Pieris Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $9.00.

Pieris Pharmaceuticals (NASDAQ PIRS) traded down 2.04% on Wednesday, reaching $5.76. 601,941 shares of the company’s stock were exchanged. Pieris Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $5.83. The firm’s market capitalization is $255.21 million. The firm has a 50-day moving average of $5.39 and a 200-day moving average of $5.39.

In related news, insider Allan Reine acquired 65,000 shares of the firm’s stock in a transaction on Thursday, August 17th. The shares were purchased at an average price of $4.82 per share, with a total value of $313,300.00. Following the acquisition, the insider now directly owns 45,000 shares in the company, valued at $216,900. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James A. Geraghty acquired 10,000 shares of the firm’s stock in a transaction on Thursday, August 17th. The shares were bought at an average cost of $4.82 per share, for a total transaction of $48,200.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $48,200. The disclosure for this purchase can be found here. Company insiders own 4.05% of the company’s stock.

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC bought a new stake in Pieris Pharmaceuticals during the 1st quarter worth about $661,000. Sphera Funds Management LTD. grew its holdings in Pieris Pharmaceuticals by 10.0% during the 2nd quarter. Sphera Funds Management LTD. now owns 1,100,000 shares of the biotechnology company’s stock worth $5,566,000 after acquiring an additional 100,000 shares during the last quarter. Creative Planning grew its holdings in Pieris Pharmaceuticals by 8.3% during the 2nd quarter. Creative Planning now owns 65,000 shares of the biotechnology company’s stock worth $329,000 after acquiring an additional 5,000 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in Pieris Pharmaceuticals during the 2nd quarter worth about $132,000. Finally, Acadian Asset Management LLC bought a new stake in Pieris Pharmaceuticals during the 2nd quarter worth about $162,000. 50.50% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Pieris Pharmaceuticals, Inc. (PIRS) to Post -$0.21 EPS” was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/zacks-brokerages-anticipate-pieris-pharmaceuticals-inc-pirs-to-post-0-21-eps/1598841.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.